Accessibility Menu

Biogen(FRA) IDP

Market Cap€27.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)+3,012%
5 Year-30%
1 Year+49%
1 Month+2%
€185.82
-0.54%
-1.00Today
Biogen last closing stock price
MetricPriceDate
Last closeEUR 165.682026-05-22
Biogen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.08%EUR 165.542026-05-15
1 month+2.02%EUR 162.402026-04-22
3 month+1.96%EUR 162.502026-02-20
Year to date+10.49%EUR 149.952025-12-30
1 year+49.06%EUR 111.152025-05-22
3 year-41.54%EUR 283.402023-05-23
5 year-30.03%EUR 236.802021-05-21
Since inception+3,012.12%EUR 6.001998-01-16

Biogen Financials at a Glance

Market Cap

€27.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€8.28K

Net Income (TTM)

€714.12

EPS (TTM)

€4.83

P/E Ratio

38.67

Dividend

€0.00

Beta (Volatility)

-0.02 (Low)

Price

€185.82

Volume

10

Open

€187.66

Previous Close

€185.82

Daily Range

€185.82 - €190.02

52-Week Range

€114.65 - €190.02

Estimated Earnings Date

N/A

IDP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Industry

Biotechnology

Sector

Health Care

Employees

7,500

CEO

Christopher A. Viehbacher, CPA

Website

www.biogen.com

IDP Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

4.53%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

2.59%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€27.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

147.75M

Volume

10

Avg. Volume

44.621

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Biogen Performance Analysis

Biogen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 8,975,861,5892.0%
20232023-12-31EUR 8,710,446,851-3.0%
20242024-12-31EUR 8,566,773,771-1.6%
20252025-12-31EUR 8,447,001,818-1.4%
Biogen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 19.86125.6%
20232023-12-31EUR 7.38-62.9%
20242024-12-31EUR 10.3440.2%
20252025-12-31EUR 7.79-24.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€2.26K

+1.0%

Gross Profit

€1.38K

+0.9%

Gross Margin

61.37%

+0.9%

Market Cap

€27.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€3.68

N/A

Employees

7,500

N/A

Net Income

€83.86

+0.1%

EBITDA

€579.85

+0.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€8.43K

+5.8%

Total Debt

€7.31K

+1.3%

Accounts Receivable

€2.10K

+1.2%

Inventory

€2.09K

+1.1%

Long Term Debt

€6.61K

+1.2%

Short Term Debt

€699.73

N/A

Return on Assets

2.74%

+0.5%

Return on Invested Capital

8.41%

+0.7%

Free Cash Flow

€354.06

+3.4%

Operating Cash Flow

€389.51

+3.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About IDP

What is the current price of Biogen?

Biogen is trading at €185.82 per share.

What is the 52-week range for Biogen?

Over the past 52 weeks, Biogen has traded between €114.65 and €190.02.

How much debt does Biogen have?

As of the most recent reporting period, Biogen reported total debt of €7.31B.

How much cash does Biogen have on hand?

Biogen reported €1.12B in cash and cash equivalents in its most recent financial results.

What is Biogen’s dividend yield?

Biogen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services